https://www.thebodypro.com/category/hiv-treatment-strategies/tag/conference-coverage
HIV Treatment Strategies

Conference Coverage

The Latest

HIV Research Preview for IDWeek 2016 Img

HIV Research Preview for IDWeek 2016

Here's a look at some of the noteworthy HIV research being presented at IDWeek 2016 in New Orleans from Oct. 25 to 30.

Four-Day-a-Week ART: Sub-Optimal Drug Levels but Few Virological Failures Img

Four-Day-a-Week ART: Sub-Optimal Drug Levels but Few Virological Failures

"Modern ART is likely to retain viral suppression with significantly less than 100% adherence," Simon Collins writes. "The results might therefore reduce anxiety associated with missed occasional missed doses in someone who otherwise has a good histo...

Beyond Cervical Cancer: Patterns and Treatment of Gynecologic Malignancies Among Women Living With HIV Img

Beyond Cervical Cancer: Patterns and Treatment of Gynecologic Malignancies Among Women Living With HIV

With HIV-positive women living longer, cancer epidemiologist Anne F. Rositch, Ph.D., looked at contemporary trends, patterns of disease, adherence to national care guidelines and barriers to treatment of non-HPV-associated gynecologic malignancies....

Community-Based Participatory Research: Addressing Ethics, Empowerment and HIV Health Disparities Img

Community-Based Participatory Research: Addressing Ethics, Empowerment and HIV Health Disparities

Community-based participatory research (CBPR) is an approach that can address social determinants of health by iinterrupting cycles of powerlessness in vulnerable communities.

Most Study Participants Were Satisfied With a New Long-Acting Injectable HIV Regimen Img

Most Study Participants Were Satisfied With a New Long-Acting Injectable HIV Regimen

A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma.

If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have Img

If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have

Benjamin Young, M.D., Ph.D., discusses the need to change perceptions of HIV harm, the role of providers as activists and his work updating the global knowledge base to reflect the 21st-century realities of HIV.

Four-Day-Per-Week Treatment Maintains HIV Control for 48 Weeks Img

Four-Day-Per-Week Treatment Maintains HIV Control for 48 Weeks

A four-day-per-week treatment regimen maintained undetectable viral loads in 96 of 100 participants of a 48-week study.

Dual Long-Acting Cabotegravir Plus Rilpivirine Injections: 48-Week Results From LATTE-2 Img

Dual Long-Acting Cabotegravir Plus Rilpivirine Injections: 48-Week Results From LATTE-2

Results from the first proof-of-principle for injection-only HIV treatment (ART) were presented at AIDS 2016.

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study Img

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study

Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.

EVG/FTC/TAF in Nanoparticles Suppresses HIV in Humanized Mice Img

EVG/FTC/TAF in Nanoparticles Suppresses HIV in Humanized Mice

Nanoparticles containing elvitegravir, emtricitabine and tenofovir alafenamide (EVG/FTC/TAF) suppressed HIV when injected into humanized mice. Viral loads remained undetectable three weeks after the last dose.